Hasil Pencarian - Saša Dimitrijević

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

    Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinica... oleh Margaret von Mehren, Michael C. Heinrich, Hongliang Shi, Sergio Iannazzo, Raymond Mankoski, Saša Dimitrijević, Gerard Hoehn, Silvia Chiroli, Suzanne George

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey

    The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey oleh Polina Pyatilova, MD, Jonathan A. Bernstein, MD, Felix Aulenbacher, Msc, Mario Sanchez Borges, MD, Saša Dimitrijević, PhD, Gerard Hoehn, PhD, Marcus Maurer, MD, Pavel Kolkhir, MD, Frank Siebenhaar, MD

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP

    P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP oleh Jason Gotlib, Andreas Reiter, Deepti Radia, Michael Deininger, Tracy George, Jens Panse, Alessandro Vannucchi, Uwe Platzbecker, Ivan Alvarez-Twose, Andrzej Mital, Olivier Hermine, Ingunn Dybedal, Elizabeth O. Hexner, Lambert Span, Ruben Mesa, Prithviraj Bose, Kirsten Pettit, Stephen Oh, Hui-Min Lin, Sasa Dimitrijevic, Javier Muñoz-González, Daniel J. Deangelo

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

    A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma oleh Graham P. Collins, Toby A. Eyre, Debora Schmitz-Rohmer, William Townsend, Rakesh Popat, Lisa Giulino-Roth, Paul A. Fields, Fatime Krasniqi, Carole Soussain, Anastasios Stathis, Nebojsa Andjelkovic, David Cunningham, Danijela Mandic, Sinisa Radulovic, Ivan Tijanic, Netanel A. Horowitz, Sabira Kurtovic, Elisabeth Schorb, Christian Schmidt, Saša Dimitrijević, Martin Dreyling

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: